Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.34 |
| ▸ | TACR1 | P25103 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.33 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29761590 | 0.89 | SIGMAR1 (0.36) | SIGMAR1KMT2AHTR2AOPRD1PDK2 | |
| SCHEMBL5790959 | 0.86 | SIGMAR1 (0.35) | SIGMAR1HTR2AOPRD1PDK2TACR1 | |
| SCHEMBL8109695 | 0.79 | SIGMAR1 (0.39) | SIGMAR1KMT2AHTR2AOPRD1OPRM1 | |
| SCHEMBL28915947 | 0.78 | SIGMAR1 (0.36) | SIGMAR1KMT2AHTR2AOPRD1OPRM1 | |
| SCHEMBL14833467 | 0.77 | SIGMAR1 (0.38) | SIGMAR1KMT2AHTR2AOPRD1OPRM1 | |
| SCHEMBL30151394 | 0.73 | NR1H2 (0.40) | OPRD1TACR1RORCOPRK1 | |
| SCHEMBL4430753 | 0.72 | HTR2A (0.36) | SIGMAR1HTR2APDK2OPRM1RORC | |
| SCHEMBL27373175 | 0.70 | SIGMAR1 (0.37) | SIGMAR1KMT2AHTR2AOPRD1OPRM1 | |
| SCHEMBL18284816 | 0.70 | SIGMAR1 (0.39) | SIGMAR1KMT2AHTR2AOPRD1OPRM1 | |
| SCHEMBL8499176 | 0.69 | SIGMAR1 (0.36) | SIGMAR1KMT2AHTR2AOPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | TIE1, TEK, KDR | SIGMAR1 4761/4885KMT2A 682/4885HTR2A 2212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.